DNTH
NASDAQ
US
Dianthus Therapeutics, Inc. - Common Stock
$86.00
▲ +$1.44
(+1.70%)
Vol 880K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.8B
ROE
-33.0%
Margin
-4104.8%
D/E
0.00
Beta
1.57
52W
$13–$45
Wall Street Consensus
22 analysts · Apr 202610
Strong Buy
11
Buy
1
Hold
0
Sell
0
Strong Sell
95.5%
Buy Rating
Price Chart
Similar Stocks
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
IMVT
Immunovant Inc
$5.1B
APGE
Apogee Therapeutics Inc
$5.2B
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17.3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
LEGN
Legend Biotech Corp
$4.0B
Earnings
Beat rate: 50.0%
Next Report
May 11, 2026
EPS Estimate: $-1.08
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.08 | — | — |
| Dec 2025 | $-1.10 | $-1.43 | $-0.33 |
| Sep 2025 | $-0.88 | $-0.97 | $-0.09 |
| Jun 2025 | $-0.89 | $-0.88 | +$0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $2.2M | $1.3M | $1.2M | $193K | $396K |
| Net Income | -$25.2M | -$28.4M | -$29.5M | -$31.6M | -$36.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -34.7% | -34.7% | -34.7% | -34.7% | -33.0% | -33.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -16388.1% | -2364.1% | -2364.1% | -2364.1% | -4104.8% | -4104.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 13.12 | 13.12 | 13.12 | 13.12 | 17.35 | 17.35 |
Key Ratios
ROA (TTM)
-31.1%
P/S (TTM)
574.05
P/B
1.8
EPS (TTM)
$-3.48
CF/Share
$-14.53
52W High
$45.46
52W Low
$13.37
$13.37
52-Week Range
$45.46
Financial Health
Free Cash Flow
-$30.6M
Net Debt
-$54.7M
Cash
$56.0M
Total Debt
$1.3M
As of Sep 30, 2025
How does DNTH compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
DNTH valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
574.1
▲
4367%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.8
▼
26%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
DNTH profitability vs Biotechnology peers
ROE
-33.0%
▲
51%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-4104.8%
▼
1331%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-31.1%
▲
33%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
DNTH financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
17.4
▲
291%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.6
▲
62%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
DNTH fundamentals radar
DNTH
Peer median
Industry
DNTH profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
DNTH vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
SOTEROPOULOS PAULA
Director · Mar 24
27594 shs
SOTEROPOULOS PAULA
Director · Mar 24
27594 shs
GARCIA MARINO
Chief Executive Officer · Mar 16
65292 shs
CARR EDWARD
Officer · Mar 12
43682 shs
GARCIA MARINO
Chief Executive Officer · Mar 12
122918 shs
RANDHAWA SIMRAT
Officer · Mar 12
33830 shs
CARR EDWARD
Officer · Mar 12
43682 shs
GARCIA MARINO
Chief Executive Officer · Mar 12
122918 shs
RANDHAWA SIMRAT
Officer · Mar 12
33830 shs
Last 90 days
Top Holders
Top 5: 35.06%FMR, LLC
14.46%
$521.8M
Wellington Management Group…
5.63%
$203.1M
Octagon Capital Advisors LP
5.43%
$196.1M
Fairmount Funds Management …
4.81%
$173.4M
Avidity Partners Management…
4.73%
$170.7M
As of Dec 31, 2025